Actinium Pharmaceuticals, Inc. (ATNM) Presents at 16th Annua
Actinium Pharmaceuticals, Inc. (ATNM) Presents at 16th Annual BIO CEO & Investor Conference Today
Actinium Pharmaceuticals, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, gave a corporate presentation today at the 16th Annual BIO CEO & Investor Conference.
Today’s presentation was held at The Waldorf-Astoria Hotel: Conrad Room, New York, NY. There was also a webcast available at: https://www.veracast.com/webcasts/bio/ceoinvestor2014/68234189.cfm/.
A replay of the webcast is being archived on Actinium’s website for 90 days following the presentation.
According to the American Cancer Society, half of all men and one third of all women will develop at least one form of cancer during their lifetime. There are more than 1.5 million new cancer cases per year in the U.S. and nearly 12.7 million worldwide, excluding non-melanoma skin cancers. Worldwide sales of biopharmaceutical products for treating cancer are approximately $50 billion per year, with U.S. sales being approximately half of that. Biopharmaceutical cancer treatments include a variety of drugs, but two categories predominate: cytotoxic chemotherapy and targeted therapies. Other approaches (e.g., hormonal therapy, phototherapy, cryotherapy, etc.) are used less frequently.
Actinium Pharmaceuticals is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The company’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies.
For more information on Actinium Pharmaceuticals, its biopharmaceutical innovations, and their progress, please visit: www.actiniumpharmaceuticals.com.
Please read full disclaimers at https://disclaimer.missionir.com